Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine

Journal of Investigative Dermatology

Volumn 130, Issue 10, 2010, Pages 2514-2516

  Busch, Christian ^a   Geisler, Jürgen ^a,b,c   Knappskog, Stian ^a   Lillehaug, Johan R ^a   Lønning, Per E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR SP1; ALKYLATING AGENT; TP53 PROTEIN, HUMAN;

CARCINOGENESIS; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN; LETTER; MELANOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; SECONDARY; SKIN NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DACARBAZINE; HUMANS; MELANOMA; PREDICTIVE VALUE OF TESTS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956873714     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.138     Document Type: Letter

References (14)

1. Balch CM, Gershenwald JE, Soong S-J et al. (2009) Final Version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
2. Bond GL, Hu W, Bond EE et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602
3. Bosserhoff AK (2006) Novel biomarkers in malignant melanoma. Clin Chim Acta 367:28-35
4. Christophorou MA, Ringshausen I, Finch AJ et al. (2006) The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443:214-217
5. Efeyan A, Serrano M (2007) p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6:1006-1010
6. Eggermont AMM, Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40:1825-1836
7. Goldstein AM, Chan M, Harland M et al. (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99-106
8. Grafstrom E, Egyhazi S, Ringborg U et al. (2005) Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin Cancer Res 11:2991-2997
9. Hartmann A, Blaszyk H, Cunningham JS et al. (1996) Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer 67:313-317
10. Jacobs JJL, Kieboom K, Marino S et al. (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164-168
11. Knappskog S, Geisler J, Arnesen T et al. (2006) A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes Chromosomes Cancer 45:1155-1163
12. Momand J, Jung D, Wilczynski S et al. (1998) The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459
13. Piette J, Neel H, Marechal V (1997) Mdm2: keeping p53 under control. Oncogene 15:1001-1010
14. Schouten JP, McElgunn CJ, Waaijer R et al. (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57